ASCO 2025
Advertisement
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Feldman presented on phase 2 patient-reported quality-of-life outcomes from the COCOON trial at the 2025 ASCO Annual Meeting.
Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Dr. Conkling shared his research insights on PD-L1 testing practices for mNSCLC within US community oncology settings.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Jessica Bauman, MD, discusses a new analysis of the REACH PC study that she presented at ASCO 2025.
Dr. Liu weighs in on the CheckMate 816 data presented at the 2025 ASCO Annual Meeting.
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
Dr. Sen explains how her team identified targetable genes that define immune suppression in small cell lung cancer.
Jennifer Carlisle, MD, shares her institution’s experience with outpatient administration of the bispecific T-cell ...
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.